Keywords: chronic renal failure; hypertension; proteinuria; renal haemodynamics; renin inhibition Background. Remikiren is an orally active renin inhibitor with established antihypertensive efficacy. As a single dose it induces renal vasodilatation, suggesting specific renal actions. Data on the renal effects of continued treatment by renin inhibition are not avail-Introduction able, either in subjects with normal, or in subjects with impaired renal function.
continuous ambulant blood pressure recordings were peravailable thus far on the renal effects of continued formed before treatment and on the fifth/sixth day of renin treatment with remikiren, or on the renal effects of inhibition. Renal haemodynamic measurements were perrenin inhibition in patients with renal function impairformed pretreatment and on the fifth day of remikiren ment and proteinuria. In the present study, therefore, treatment. On the first and the last treatment day timed we report on the renal and systemic effects of continued blood samples were drawn for measurement of plasma renin treatment for 8 days the renin inhibitor remikiren in activity (PRA), immunoreactive renin (irR), and angII. hypertensive patients with normal renal function, as well as in patients with impaired renal function and Methods proteinuria.
Blood pressure was measured by an automatic non-invasive device: DinamapB, Criticon Inc, Tampa Florida, and the
Subjects and methods
SpacelabsB respectively. Mean arterial pressure (MAP) was calculated as diastolic blood pressure plus one-third of the
Patients and protocol
pulse pressure. For each hour the mean value was calculated. Urinary sodium, potassium and creatinine were measure by Fourteen caucasian patients with mild to moderate hyperten-a standard autoanalyser technique (SMA-C, TechniconB, sion (diastolic blood pressure between 90 and 115 mmHg) Tarrytown, NY ). Urinary protein was measured by the were included. Patients had either essential hypertension with pyrogallol red-molybdate method. Blood samples for measnormal renal function (creatinine clearance >90 ml/min; n= urement of irR and PRA were collected into Vacutainer 8, all male) or impaired renal function due to non-diabetic tubes at room temperature with EDTA as an anticoagulant. renal disease (a stable creatinine clearance <60 ml/min; n= Blood samples for angII were collected into pre-chilled 6, two female, four male). No other clinical relevant target Vacutainer tubes containing an inhibitor cocktail consisting organ damage was allowed. Excluded were patients with of EDTA, the ACEi cilazaprilat, and the renin inhibitor Ro other secondary forms of hypertension, patients over-42-5892, in order to prevent the formation of angII during weight with more than 120% of their ideal body weight processing. All samples were immediately separated; then (Metropolitan Insurance Life Table) , patients with a history plasma was immediately stored at −20 until analysis. The of alcohol or drug abuse, and women of childbearing poten-irR was determined using the renin IRMA Pasteur kit. This tial or taking birth-control pills. All subjects gave their method has a coefficient of variation of 15.9% (inter-assay) informed consent and the study was approved by the Ethical and 6.6% (intra-assay, both at 31 pg/ml ). PRA was measured Committee of the Hospital.
as the quantity of generated angI measured by RIA (RianenB Median age of the patients was 53 years (range 32-69). Ang I RIA kit). AngII was determined by the Nichols The median body mass index at baseline was 26.1 kg/m2 Institute Diagnostics Ang II RIA, with a coefficient of (95% CI 24.8-27.5). In the patients with essential hyperten-variation of 5.1% (inter-assay, mean value 31 pg/ml ) and 4% sion, creatinine clearance at entry was 120±5 ml/min (range (intra-assay, mean value 42 pg/ml ). During analysis plasma 102-149 ml/min). In the renal patients it was 42±4 ml/min was first separated from plasma proteins by ethanol extrac-(range 32-58). Histological diagnoses were glomerulo-tion. The extracted plasma angII was measured in a sensitive sclerosis (3); membranous glomerulopathy (2), and IgA and specific competitive protein-binding radioimmunoassay. nephropathy (1). Systolic blood pressure at entry was The lower limit of detection is 3.6 pg/ml. Circulating levels 154±2 mmHg (range 130-161) and diastolic blood pressure of remikiren were determined by the radioinhibitor assay of was 100±2 mmHg (range 90-111); these values were similar Cumin et al. [18] , using 3H RO 42-5892 as a tracer. for the essential hypertensives and the renal patients. In the Glomerular filtration rate (GFR) and effective renal plasma essential hypertensives median albuminuria at entry was flow ( ERPF ) were measured as the renal clearances of 13.3 mg/24 h (range 5.5-30.1 mg/24 h). In the renal patients constantly infused [125I ]iothalamate and [131I ]hippuran nephrotic range proteinuria was present, with a median of respectively. Correction for urine collection errors was 10.2 g/24 h (range 6.6-13.1 g/24 h) at entry. applied as described previously [19] . The day-to-day coeffiThe study was performed on an ambulatory in-hospital cient of variation of this method is 2.2 and 5% respectively. basis, and was designed in a single-blind, longitudinal order. Values are normalized for body surface area. Filtration All antihypertensives had been withdrawn at least 3 weeks fraction (FF ) is calculated as the ratio of GFR/ERPF. Renal prior to the study, with the exception of one proteinuric vascular resistance (RVR) is calculated as the ratio of MAP patient in whom diuretic treatment was necessary. The dose and ERPF. of the diuretic was kept constant throughout the protocol. This patient was excluded from the analysis of electrolyte balance. After the screening and wash-out period the patients Data analysis were hospitalized for 18 days. During hospitalization they received a diet containing 50 mmol sodium, 100 mmol potas-Results are presented as means±SEM. Data sets that are not normally distributed are presented as medians and ranges. sium, 60 g protein, and 2500 ml fluids daily.
After a 5-day run-in period in the hospital, the patients Sodium and potassium balance are calculated by subtracting 24-h urinary excretion from the individual mean excretion were studied during a 5-day baseline period without treatment. During this baseline period, stabilization of blood during the last 2 pretreatment study days. Data on hormonal responses, blood pressure, renal haemodynamics, and electropressure, proteinuria, and electrolyte excretion was established. Subsequently, remikiren treatment (600 mg orally lyte balance are presented for all patients taken together.
Data on the responses of proteinuria and albuminuria are o.i.d., adminstered each day at noon) was given for 8 days. Twenty-four-hour urine was collected daily for determination presented for the renal patients and the essential hypertensives separately. Statistical analysis was performed by a paired, of sodium, potassium, creatinine, urea, and protein. Blood pressure was measured daily between 11 and 12 a.m., at non-parametric ANOVA (Friedmann) for repeated measurements, followed by Dunn's correction for multiple compar-5-min intervals, in the supine position. In addition, 48 h Effects of continued treatment with remikiren in hypertensive patients 639 isons, unless otherwise indicated. A standard linear least-on day 8 was increased by 30% as compared to presquares regression analysis was used to assess the correlation treatment values (range −35 to 82%; P<0.05). between different parameters. Significance was assumed at a Remikiren plasma levels reached their peak within two-sided P value <0.05. 30 min after oral administration both on the first (median C max 60.2, range 6.1-252 ng/ml ) as well as the last day of treatment (C max 54.2, range
Results

32
.7-342 ng/ml ). Remikiren was rapidly cleared from the plasma thereafter. No differences in pre-treatment The efficacy of remikiren in blocking the RAS, as well hormonal parameters or in the humoral response to as the drug levels, are shown in Figure 1 . PRA fell treatment were observed between the renal patients maximally within 30 min after the first dose of remi-and the essential hypertensive patients. kiren and remained suppressed during the 12 h followIn Figure 2 the time course of mean blood pressure ing. At day 8, trough values were 65% below (range at trough (n=14) is given. It shows that MAP fell 2-87%, P<0.05) the pre-treatment value on day 1, significantly, from 108±2 to 96±2 mmHg. The effect indicating inhibition of PRA throughout the day. After on diurnal blood pressure profile is given in Figure 3 . dosing, a further decrease to almost undetectable levels It shows that MAP is reduced throughout 24 h and occurred. AngII fell up to 6 h after the first dose, but the trough value at day 8 was not significantly different from the pre-treatment value. The level of irR increased until 4 h after the first dose, whereas the trough value well as on days 6 and 7 during remikiren treatment (broken lines).
that heart rate did not change. The fall in blood pressure was similar for systolic and diastolic blood pressure. The peak fall in MAP was −11.2±0.8% (range −7.5 to −17.4, average of a 4-h period) on day 7 with a corresponding trough value of −6±1% (range −0.1 to −16.2). This resulted in a trough to peak ratio of 0.53±0.11.The fall in blood pressure was more pronounced in the chronic renal failure patients (−13.3±1.1%) than in the essential hypertensive patients (−9.6±0.7%; P<0.01, Mann-Whitney). The renal haemodynamic effects are shown for individual patients in Figure 4 . It shows that GFR remained stable, with a mean value of 65±9 ml/min/1.73 m2 before treatment, and a mean value of 63±8 ml/min during remikiren. ERPF increased from 301±35 to 330±36 ml/min (P<0.05). As a result, FF fell by 10±2% (range 1-19%; P<0.01). Mean MAP was lowered from 106.7±1.9 to 97.9±1.9 mmHg (P<0.001) during the renal haemodynamic measurements, accordingly a decrease in RVR of 15±2% (range 2-30%) could be calculated (P<0.01).
Remikiren exerted significant effects on the renal excretion of sodium and potassium ( Figure 5 ). During the pre-treatment period excretion had stabilized in all patients, with a pre-treatment value of 37±2 (range 24-44) mmol/24 h for sodium and of 88±1 (range 82-100) mmol/24 h for potassium, showing excellent Figure 5 ). In the chronic renal failure patients both the sodium loss aldosterone was observed with a return to values not (−98±31 vs −72±32 in essential hypertensive patients) and the potassium retention (60±13 vs 42±11 in essential hypertensive patients) tended to be somewhat more pronounced, although not significantly so (both P<0.1, NS). The effect of remikiren on proteinuria in the six renal patients is shown in Figure 6 , together with the effect on MAP in these patients. During the in-hospital run-in period, proteinuria had gradually fallen to values below those obtained at entry, with stabilization during the 5-day baseline period. Median baseline value was 5.8 g/24 h (range 2.4-11.9). Remikiren induced a gradual and significant fall in proteinuria, with a maximal decrease of 27% (median value, range −38 to −18%) (P<0.01). In the essential hypertensive patients a reduction in renal protein leakage was found as well. Median pre-treatment albuminuria after stabilization in hospital was 7.8 mg/24 h (range 4.3-10.4 mg/24 h); after 8 days treatment with remikiren, albuminuria had fallen by a median of −20% (range −61 to −1%, P<0.05).
No significant effects on serum electrolytes, albumin or cholesterol were observed during treatment. No  Fig. 4 . The individual effects of remikiren on glomerular filtration side-effects were experienced by any of the patients rate (GFR, ml/min/1.73 m2) and effective renal plasma flow ( ERPF, ml/min/1.73 m2). during this study.
in accordance with rapid biliary elimination of the drug, but does not rule out the possibility of higher tissue concentrations in patients with impaired renal function.
The fall in blood pressure was sustained throughout 24 h, with a high trough-to-peak ratio. In line with the measurements of PRA and irR, this indicates efficacy throughout 24 h. A previous study in essential hypertensive patients [8] found a somewhat less pronounced blood pressure response with renin inhibition. Several factors could account for the more pronounced blood pressure response in our study. These include the use of a different remikiren compound ( later generation), the in-hospital study design, the use of a sodiumrestricted diet, and finally the different patient population. Interestingly, in our population the six patients with renal function impairment had a more pronounced blood-pressure response than the essential hypertensive patients. Whether this is due to pharmacokinetic factors (i.e. higher drug levels) or to pharmaco- Fig. 6 . Effect of remikiren (mean and 95% CI ) on blood pressure dynamic factors (such as a greater contribution of the (MAP, % change from baseline) and urinary protein ( Uprot, % RAS in vasomotor tone) cannot be ascertained from change from baseline). *P<0.05 vs mean of last 2 baseline days. the present data. Hormonal parameters were similar for the renal patients and the essential hypertensive Discussion patients, but this does not exclude differences in activity of tissue RAS.
Our study is the first to provide data on the renal Continued treatment for 8 days with renin inhibitor remikiren induced distinct systemic as well as renal effects of continued treatment with renin inhibition.
This allowed an assessment of the effects on sodium effects in hypertensive patients with normal and impaired renal function. A fall in blood pressure was and potassium balance. Remikiren induced a net negative sodium balance-in spite of the fall in blood observed that is sustained throughout the day. Remikiren induced a rise in ERPF and a fall in RVR, pressure-and a concomitant positive potassium balance in both essential hypertensive and renal patients. demonstrating renal vasodilatation. GFR was unchanged, resulting in a fall in FF. Renal protein The combination of sodium loss and potassium gain was also reported for ACE inhibition, and is usually excretion decreased during remikiren administration, not only in patients with overt nephrotic-range pro-attributed to a suppression of aldosterone. The gradual return to baseline values of aldosterone after its initial teinuria, but also in the essential hypertensive patients in whom albuminuria fell significantly during remikiren decline-a feature that we have previously reported to occur with ACE inhibition as well [24] -presumably treatment. Finally, a net negative sodium balance was observed, associated with a positive potassium balance. reflects stimulation of aldosterone by the positive potassium balance, as the persistently elevated PRA The measurement of PRA and irR shows that this once-daily dose of remikiren elicited RAS inhibition indicates an ongoing drug effect on RAS activity.
Remikiren induced renal vasodilatation, with a signithroughout the 24 h. This was not reflected, however, by a 24-h suppression of angII. This dissociation is in ficant rise in ERPF despite the fall in blood pressure.
The renal haemodynamic profile, with a fall in FF, line with previous studies [20] . The peak drug levels immediately after dosing as well as the rapid clearance suggests that efferent arteriolar vasodilatation predominates over afferent vasodilatation. Such renal vasodilfrom the plasma therafter confirms the pharmacokinetic profile of remikiren, as described earlier atation may well have facilitated renal sodium loss.
The effects of remikiren on renal haemodynamics are [9, 11, 21] . Experimental data have shown that remikiren levels in tissue exceed those in plasma [22, 23] . It in line with those with other modes of blocking the RAS, such as ACE inhibitors and AT 1 -receptor blockhas been hypothesized that the kidney is the main target tissue for remikiren and that retention of the ers [3, 25] . Interestingly, this renal profile occurred irrespective the presence of renal functional impairdrug in this organ may provide a reservoir of drug within the body [23] . This would explain the sustained ment. In renal patients this renal haemodynamic profile may contribute to long term renoprotection [26 ] . pharmacodynamic effects after single doses of remikiren despite undetectable plasma drug levels [8] [9] [10] .
Treatment with remikiren was associated with a gradual, significant reduction of urinary protein loss, Thus it is likely, in spite of the low oral bioavailability, that enough drug is available at the target level. We both in overt proteinuria and in the normoalbuminuria in the essential hypertensive patients. This questioned whether an impaired renal function would lead to plasma accumulation of the drug. This was not is likely to indicate renoprotective potential, as reduction in proteinuria has consistently been shown to the case, even with a GFR as low as 20 ml/min. This 
